Leukemia, Lymphoma, Myeloma Cancer News |Hematologic & Blood

Hematologic Cancers News

HEMATOLOGIC CANCER ADVISOR

Hematologic Cancers News

FDA_accelerated approval

Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Next post in Chronic Lymphocytic Leukemia